These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32852744)

  • 21. Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Clinical Parameters in Patients with Heart Failure.
    Yazaki M; Nabeta T; Takigami Y; Eda Y; Fujita T; Iida Y; Ikeda Y; Ishii S; Ako J
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256345
    [No Abstract]   [Full Text] [Related]  

  • 22. Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice.
    Nishide S; Uchida J; Matsunaga S; Tokudome K; Yamaguchi T; Kabei K; Moriya T; Miura K; Nakatani T; Tomita S
    J Pharmacol Sci; 2020 Jun; 143(2):122-126. PubMed ID: 32199747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roxadustat: First Global Approval.
    Dhillon S
    Drugs; 2019 Apr; 79(5):563-572. PubMed ID: 30805897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor-Prolyl Hydroxylase Inhibitor.
    Kokado Y; Kawai K; Nanjo T; Kinoshita S; Kondo K
    Clin Ther; 2021 Aug; 43(8):1408-1418.e5. PubMed ID: 34511184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lurbinectedin: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(13):1345-1353. PubMed ID: 32816202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desidustat: First Approval.
    Dhillon S
    Drugs; 2022 Jul; 82(11):1207-1212. PubMed ID: 35834123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
    Zhang X; Lei Y; Hu T; Wu Y; Li Z; Jiang Z; Yang C; Zhang L; You Q
    J Med Chem; 2020 Sep; 63(17):10045-10060. PubMed ID: 32787144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
    Su K; Li Z; Yu Y; Zhang X
    Drug Discov Today; 2020 Jul; 25(7):1262-1269. PubMed ID: 32380083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Chavan A; Burke L; Sawant R; Navarro-Gonzales P; Vargo D; Paulson SK
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):950-958. PubMed ID: 33661566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
    Haase VH
    Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S110-S124. PubMed ID: 28449418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vadadustat for Anemia in Patients with Dialysis-Dependent or Non-Dialysis-Dependent Chronic Kidney Disease.
    Bunn HF
    N Engl J Med; 2021 Oct; 385(16):e56. PubMed ID: 34644481
    [No Abstract]   [Full Text] [Related]  

  • 33. Vadadustat for Anemia in Patients with Dialysis-Dependent or Non-Dialysis-Dependent Chronic Kidney Disease. Reply.
    Chertow GM; Eckardt KU
    N Engl J Med; 2021 Oct; 385(16):e56. PubMed ID: 34644482
    [No Abstract]   [Full Text] [Related]  

  • 34. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New expectations in the treatment of anemia in chronic kidney disease.
    López-Gómez JM; Abad S; Vega A
    Nefrologia; 2016; 36(3):232-6. PubMed ID: 27137103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23.
    Ikeda Y
    Kidney Int; 2021 Jul; 100(1):14-16. PubMed ID: 34154707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy: PHD inhibitors correct anaemia in CKD.
    Carney EF
    Nat Rev Nephrol; 2016 Jan; 12(1):3. PubMed ID: 26553512
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis.
    Xie D; Wang J; Wu X; Li M
    Int Urol Nephrol; 2018 Dec; 50(12):2201-2206. PubMed ID: 30073615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
    Joharapurkar AA; Pandya VB; Patel VJ; Desai RC; Jain MR
    J Med Chem; 2018 Aug; 61(16):6964-6982. PubMed ID: 29712435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro studies of hypoxia inducible factor-prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control.
    Philip M; Karakka Kal AK; Subhahar MB; Karatt TK; Mathew B; Perwad Z
    Drug Test Anal; 2022 Feb; 14(2):317-348. PubMed ID: 34714596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.